drugset / Trial / NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT05750628

Phase 2 Recruiting 327 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Timeline

Start
2024-01-23
Primary completion
2026-06-09
Completion
2026-06-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether-lumefantrine Unknown
Subject INE963 Small molecule Oral
Subject KLU156 Unknown Oral
Subject cipargamin Small molecule Oral